The secrets in your baby's genes

What It Covers

Doctor Robert Green's BabySeq project sequences healthy newborns' DNA to detect genetic disease risks. The trial finds 12% of babies carry mutations for treatable conditions, sparking debate about benefits versus psychological harms of predictive genomic screening.

Key Questions Answered

• •Disease prevalence data: BabySeq screening reveals 4% of healthy newborns carry mutations in 400 treatable disease genes, expanding to 12% when including 5,000 genes for untreatable or adult-onset conditions—far exceeding previous estimates of congenital problems.
• •Psychological impact evidence: Randomized controlled trials treating genetic information like a pharmaceutical drug show parents experience less distress than predicted, recover quickly from concerning results, and report feeling empowered rather than anxious about their child's genetic risks.
• •Surveillance trade-offs: Identifying genetic risks requires ongoing medical monitoring through childhood, potentially creating patient-in-waiting anxiety, over-diagnosis, and unnecessary treatments for conditions that may never manifest, while missing cases detected by traditional newborn screening methods.
• •Equity implementation challenges: Whole genome sequencing costs create access disparities, with wealthy families accessing preventive information first. Seven U.S. states will pilot integration into public newborn screening laboratories to test equitable delivery models reaching 99.9% of births.